AU2017295628B2 - Heterocyclic compound used as FGFR inhibitor - Google Patents

Heterocyclic compound used as FGFR inhibitor Download PDF

Info

Publication number
AU2017295628B2
AU2017295628B2 AU2017295628A AU2017295628A AU2017295628B2 AU 2017295628 B2 AU2017295628 B2 AU 2017295628B2 AU 2017295628 A AU2017295628 A AU 2017295628A AU 2017295628 A AU2017295628 A AU 2017295628A AU 2017295628 B2 AU2017295628 B2 AU 2017295628B2
Authority
AU
Australia
Prior art keywords
pyrid
methyl
compound
mmol
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017295628A
Other languages
English (en)
Other versions
AU2017295628A1 (en
Inventor
Norman Xianglong Kong
Zhixiang Zheng
Chao Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Innocare Pharma Tech Co Ltd
Original Assignee
Nanjing Innocare Pharma Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Innocare Pharma Tech Co Ltd filed Critical Nanjing Innocare Pharma Tech Co Ltd
Publication of AU2017295628A1 publication Critical patent/AU2017295628A1/en
Application granted granted Critical
Publication of AU2017295628B2 publication Critical patent/AU2017295628B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2017295628A 2016-07-13 2017-06-13 Heterocyclic compound used as FGFR inhibitor Ceased AU2017295628B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610550151.3 2016-07-13
CN201610550151.3A CN107619388A (zh) 2016-07-13 2016-07-13 作为fgfr抑制剂的杂环化合物
PCT/CN2017/088038 WO2018010514A1 (zh) 2016-07-13 2017-06-13 作为fgfr抑制剂的杂环化合物

Publications (2)

Publication Number Publication Date
AU2017295628A1 AU2017295628A1 (en) 2019-02-21
AU2017295628B2 true AU2017295628B2 (en) 2021-05-13

Family

ID=60951887

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017295628A Ceased AU2017295628B2 (en) 2016-07-13 2017-06-13 Heterocyclic compound used as FGFR inhibitor

Country Status (12)

Country Link
US (1) US10590109B2 (https=)
EP (1) EP3489223A4 (https=)
JP (1) JP6896852B2 (https=)
KR (1) KR102386428B1 (https=)
CN (2) CN107619388A (https=)
AU (1) AU2017295628B2 (https=)
CA (1) CA3030070A1 (https=)
MX (1) MX386089B (https=)
PH (1) PH12019500036A1 (https=)
RU (1) RU2742485C2 (https=)
SG (2) SG10202013038VA (https=)
WO (1) WO2018010514A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3663285B1 (en) * 2017-08-04 2024-01-24 Abbisko Therapeutics Co., Ltd. Formylpyridine derivative having fgfr4 inhibitory activity, preparation method therefor and use thereof
AU2018346597B2 (en) 2017-10-06 2023-07-13 Forma Therapeutics, Inc. Inhibiting Ubiquitin Specific Peptidase 30
CN108129471A (zh) * 2018-03-20 2018-06-08 韩邦森 一种噻唑取代嘧啶类化合物的合成工艺
JP7449242B2 (ja) 2018-05-17 2024-03-13 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物
JP7530889B2 (ja) 2018-10-05 2024-08-08 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ３０（ｕｓｐ３０）阻害剤として作用する縮合ピロリン
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
CN111039874B (zh) * 2019-12-13 2022-11-04 南开大学 一种2-胺基-4-甲基嘧啶化合物的零废水制备方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1508130A (zh) * 2002-12-18 2004-06-30 中国科学院大连化学物理研究所 N-苯基-n’-嘧啶基取代脲类衍生物的合成方法
CN1678311A (zh) * 2002-06-27 2005-10-05 诺沃挪第克公司 用作治疗剂的芳基羰基衍生物
WO2006000420A1 (en) * 2004-06-24 2006-01-05 Novartis Ag Pyrimidine urea derivatives as kinase inhibitors
WO2006009741A1 (en) * 2004-06-23 2006-01-26 Eli Lilly And Company Kinase inhibitors
WO2007017577A1 (fr) * 2005-08-04 2007-02-15 Aventis Pharma S.A. 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2007059341A2 (en) * 2005-11-16 2007-05-24 Sgx Pharmaceuticals, Inc. Pyrazolothiazole protein kinase modulators
WO2008065282A2 (fr) * 2006-11-10 2008-06-05 Sanofi-Aventis Pyrazoles substituees, compositions les contenant, procede de fabrication et utilisation
CN102471280A (zh) * 2009-07-03 2012-05-23 赛诺菲 吡唑衍生物、其制备及其治疗用途
WO2013024427A1 (en) * 2011-08-16 2013-02-21 Glenmark Pharmaceuticals S.A. Novel urea derivatives as tec kinase inhibitors and uses thereof
WO2016151499A1 (en) * 2015-03-25 2016-09-29 Novartis Ag Formylated n-heterocyclic derivatives as fgfr4 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2850652B1 (fr) 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
WO2007064931A2 (en) 2005-12-02 2007-06-07 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TN2016000115A1 (en) * 2013-10-25 2017-07-05 Novartis Ag Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors.
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1678311A (zh) * 2002-06-27 2005-10-05 诺沃挪第克公司 用作治疗剂的芳基羰基衍生物
CN1508130A (zh) * 2002-12-18 2004-06-30 中国科学院大连化学物理研究所 N-苯基-n’-嘧啶基取代脲类衍生物的合成方法
WO2006009741A1 (en) * 2004-06-23 2006-01-26 Eli Lilly And Company Kinase inhibitors
WO2006000420A1 (en) * 2004-06-24 2006-01-05 Novartis Ag Pyrimidine urea derivatives as kinase inhibitors
CN101035769A (zh) * 2004-06-24 2007-09-12 诺瓦提斯公司 作为激酶抑制剂的嘧啶脲衍生物
WO2007017577A1 (fr) * 2005-08-04 2007-02-15 Aventis Pharma S.A. 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
CN101304998A (zh) * 2005-08-04 2008-11-12 艾文蒂斯药品公司 取代的7-氮杂-吲唑类，含有其的组合物，制备方法及其用途
WO2007059341A2 (en) * 2005-11-16 2007-05-24 Sgx Pharmaceuticals, Inc. Pyrazolothiazole protein kinase modulators
WO2008065282A2 (fr) * 2006-11-10 2008-06-05 Sanofi-Aventis Pyrazoles substituees, compositions les contenant, procede de fabrication et utilisation
CN102471280A (zh) * 2009-07-03 2012-05-23 赛诺菲 吡唑衍生物、其制备及其治疗用途
WO2013024427A1 (en) * 2011-08-16 2013-02-21 Glenmark Pharmaceuticals S.A. Novel urea derivatives as tec kinase inhibitors and uses thereof
WO2016151499A1 (en) * 2015-03-25 2016-09-29 Novartis Ag Formylated n-heterocyclic derivatives as fgfr4 inhibitors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry Letters, 2006, 16, 2293-98 *
Bioorganic & Medicinal Chemistry Letters, 2016, 26(13), 3067-72 *
European Journal of Medicinal Chemistry, 2016, 115, 311-325 *
Heterocycles, 2006, 67(1), 337-351 *
Organic Letters, 2013, 15(22), 5742-45 *

Also Published As

Publication number Publication date
PH12019500036A1 (en) 2019-10-28
JP6896852B2 (ja) 2021-06-30
JP2019522055A (ja) 2019-08-08
KR102386428B1 (ko) 2022-04-14
RU2019100164A (ru) 2020-08-13
CN108349896A (zh) 2018-07-31
RU2742485C2 (ru) 2021-02-08
MX2019000451A (es) 2019-09-27
KR20190032420A (ko) 2019-03-27
SG10202013038VA (en) 2021-01-28
EP3489223A1 (en) 2019-05-29
RU2019100164A3 (https=) 2020-08-27
MX386089B (es) 2025-03-18
US20190144427A1 (en) 2019-05-16
EP3489223A4 (en) 2020-01-15
SG11201900298RA (en) 2019-02-27
AU2017295628A1 (en) 2019-02-21
CA3030070A1 (en) 2018-01-18
US10590109B2 (en) 2020-03-17
CN108349896B (zh) 2021-06-01
CN107619388A (zh) 2018-01-23
WO2018010514A1 (zh) 2018-01-18

Similar Documents

Publication Publication Date Title
AU2017295628B2 (en) Heterocyclic compound used as FGFR inhibitor
EP4263545B1 (en) Prmt5 inhibitors
TWI725266B (zh) Fgfr4抑制劑、其製備方法與藥學上的應用
CN105524048B (zh) 作为fgfr激酶抑制剂的吲唑类化合物及其制备和应用
CN109020957B (zh) 作为mnk抑制剂的杂环化合物
CN114981268A (zh) 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用
WO2019223766A1 (zh) 一种fgfr抑制剂、其制备方法和在药学上的应用
JP6564406B2 (ja) カゼインキナーゼ１デルタ／イプシロン阻害剤としてのイミダゾ−ピリダジン誘導体
CA3032921A1 (en) Heterocyclic compounds as fgfr inhibitors
KR20150126391A (ko) 신규 피리미딘 및 피리딘 화합물 및 이들의 용도
KR20200138306A (ko) 헤테로시클릭 화합물
CN111039941B (zh) 一种含氮杂环化合物、其制备方法及应用
WO2014192868A1 (ja) 環状アミノメチルピリミジン誘導体
JP2022523351A (ja) ヘテロアリール誘導体およびこれを有効成分として含む薬学的組成物
WO2020200154A1 (zh) 一类噻吩并氮杂环类化合物、制备方法和用途
WO2019141096A1 (zh) 取代脲类化合物及其制备方法和用途
CN108727368A (zh) 含氮稠杂环化合物、其制备方法、中间体、组合物和应用
HK1245261A1 (zh) 作为fgfr抑制剂的杂环化合物
WO2023082044A1 (zh) 5-醛基杂环酰胺类化合物及其应用
CN116102549A (zh) 5-醛基杂环酰胺类化合物及其应用
TWI423974B (zh) 三氮唑並吡啶和三氮唑並吡嗪化合物及其組合物和應用
Newton et al. PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS
HK1258833A1 (zh) 作为fgfr抑制剂的杂环化合物
HK1258833B (zh) 作为fgfr抑制剂的杂环化合物
TW201305153A (zh) 三唑並吡啶和三唑並吡嗪化合物及其組合物和應用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired